RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+9.4%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$958M
AUM Growth
+$958M
(+0.36%)
Cap. Flow
+$840K
Cap. Flow
% of AUM
0.09%
Top 10 Holdings %
Top 10 Hldgs %
27.27%
Holding
97
New
7
Increased
32
Reduced
18
Closed
4
Top Buys
| 1 |
HCA Healthcare
HCA
|
$11.3M |
| 2 |
Medtronic
MDT
|
$8.55M |
| 3 |
Bio-Techne
TECH
|
$7.46M |
| 4 |
Tenet Healthcare
THC
|
$6.18M |
| 5 |
Cencora
COR
|
$6.13M |
Top Sells
| 1 |
ABMD
Abiomed Inc
ABMD
|
$21.7M |
| 2 |
Intuitive Surgical
ISRG
|
$11.9M |
| 3 |
UnitedHealth
UNH
|
$8.91M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$8.1M |
| 5 |
Thermo Fisher Scientific
TMO
|
$6.88M |
Sector Composition
| 1 | Healthcare | 99.1% |
| 2 | Industrials | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$657B
| $32.2M | 3.36% | 88,000 -9,000 | -9% | -$3.29M |
|
|
2
Cencora
COR
$56.5B
| $28.7M | 2.99% | 173,000 +37,000 | +27% | +$6.13M |
|
|
3
Medtronic
MDT
$119B
| $27.2M | 2.84% | 350,000 +110,000 | +46% | +$8.55M |
|
4
Boston Scientific
BSX
$156B
| $27.1M | 2.82% | 585,000 -110,000 | -16% | -$5.09M |
|
5
Regeneron Pharmaceuticals
REGN
$61.5B
| $26.7M | 2.79% | 37,000 +5,000 | +16% | +$3.61M |
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $26.3M | 2.74% | 254,000 +17,000 | +7% | +$1.76M |
|
7
Merck
MRK
$210B
| $23.9M | 2.49% | 215,000 | – | – |
|
8
Gilead Sciences
GILD
$140B
| $23.2M | 2.42% | 270,000 | – | – |
|
9
Vertex Pharmaceuticals
VRTX
$100B
| $23.1M | 2.41% | 80,000 -16,000 | -17% | -$4.62M |
|
10
Elevance Health
ELV
$71.8B
| $23.1M | 2.41% | 45,000 +5,000 | +13% | +$2.56M |
|
|
11
Tenet Healthcare
THC
$16.3B
| $23M | 2.4% | 470,750 +126,750 | +37% | +$6.18M |
|
|
12
Thermo Fisher Scientific
TMO
$186B
| $22M | 2.3% | 40,000 -12,500 | -24% | -$6.88M |
|
|
13
HCA Healthcare
HCA
$94.5B
| $21.6M | 2.25% | 90,000 +47,000 | +109% | +$11.3M |
|
14
Becton Dickinson
BDX
$55.3B
| $21.1M | 2.2% | 83,000 -2,000 | -2% | -$509K |
|
15
AbbVie
ABBV
$372B
| $21M | 2.19% | 130,000 -19,626 | -13% | -$3.17M |
|
16
Cigna
CI
$80.3B
| $20.5M | 2.14% | 62,000 -13,000 | -17% | -$4.31M |
|
17
Jazz Pharmaceuticals
JAZZ
$7.75B
| $20.4M | 2.13% | 128,000 -3,500 | -3% | -$558K |
|
|
18
UnitedHealth
UNH
$281B
| $20.1M | 2.1% | 38,000 -16,800 | -31% | -$8.91M |
|
19
Humana
HUM
$36.5B
| $20M | 2.08% | 39,000 -5,000 | -11% | -$2.56M |
|
20
Pfizer
PFE
$141B
| $17.9M | 1.87% | 350,000 | – | – |
|
21
Johnson & Johnson
JNJ
$427B
| $17.7M | 1.84% | 100,000 | – | – |
|
22
Alnylam Pharmaceuticals
ALNY
$58.5B
| $17.3M | 1.81% | 73,000 -2,000 | -3% | -$475K |
|
23
BioNTech
BNTX
$24B
| $16.4M | 1.71% | 109,000 +10,000 | +10% | +$1.5M |
|
24
CVS Health
CVS
$92.8B
| $15.9M | 1.66% | 171,000 -54,000 | -24% | -$5.03M |
|
25
Cooper Companies
COO
$13.4B
| $15.5M | 1.62% | 47,000 +98 | +0.2% | +$32.4K |
|